key: cord-0933900-j18hfmn5
authors: Weiner, J.; Suwalski, P.; Holtgrewe, M.; Thibeault, C.; Mueller, M.; Patriki, D.; Quedenau, C.; Krueger, U.; Helbig, E. T.; Lippert, L.; Stubbemann, P.; Real, L. M.; Sanchez, J. M.; Pineda, J. A.; Fernandez-Fuertes, M.; Wang, X.; Karadeniz, Z.; Saccomanno, J.; Doehn, J.-M.; Hubner, R.-H.; Hinzmann, B.; Salvo, M.; Blueher, A.; Siemann, S.; Jurisic, S.; Beer, H.; Rutishauser, J.; Wiggli, B. J.; Schmid, H. R.; Danninger, K.; Binder, R.; Corman, V. M.; Muehlemann, B.; Braun, A.; Ripke, S.; Jones, T. C.; Suttorp, N.; Witzenrath, M.; Hippenstiel, S.; Zemojtel, T.; Skurk, C.; Poller, W.; Borodina, T.
title: HLA-C* 04:01 is a Genetic Risk Allele for Severe Course of COVID-19
date: 2020-12-24
journal: nan
DOI: 10.1101/2020.12.21.20248121
sha: 10d6cae41ba8127b9c4171088766c567ca040946
doc_id: 933900
cord_uid: j18hfmn5

Background Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been increasing demand to identify predictors of severe clinical course in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human leukocyte antigen alleles (HLA) have been suggested as potential genetic host factors. We sought to evaluate this hypothesis by conducting an international multicenter study using HLA sequencing with subsequent independent validation. Methods We analyzed a total of 332 samples. First, we enrolled 233 patients in Germany, Spain, and Switzerland for HLA and whole exome sequencing. Furthermore, we validated our results in a public data set (United States, n=99). Patients older than 18 years presenting with COVID-19 were included, representing the full spectrum of the disease. HLA candidate alleles were identified in the derivation cohort (n=92) and tested in two independent validation cohorts (n=240). Results We identified HLA-C* 04:01 as a novel genetic predictor for severe clinical course in COVID-19. Carriers of HLA-C* 04:01 had twice the risk of intubation when infected with SARS-CoV-2 (hazard ratio 2.1, adjusted p-value=0.0036). Importantly, these findings were successfully replicated in an independent data set. Furthermore, our findings are biologically plausible, as HLA-C* 04:01 has fewer predicted bindings sites with relevant SARS-CoV-2 peptides as compared to other HLA alleles. Exome sequencing confirmed findings from HLA analysis. Conclusions HLA-C* 04:01 carriage is associated with a twofold increased risk of intubation in patients infected with SARS-CoV-2. Testing for HLA-C* 04:01 could have clinical implications to identify high-risk patients and individualize management.

SARS-CoV-2 15 , similar to that found in actual clinical samples from patients with SARS-CoV-1 14 .

While HLA-B* 46:01 frequency is 17% in Asia, where these data were obtained, the allele frequency is 0.05% in Germany and <0.01% in Spain, where the largest part of our study was conducted (http://www.allelefrequencies.net) 16 . Therefore, we suspected that if an HLA risk allele was identified, it would differ from the one discovered during the SARS-CoV pandemic in Asia.

To test our hypothesis, we collected blood samples from patients infected with SARS-CoV-2 for HLA sequencing during the first peak of the European COVID-19 pandemic. Enrollment centers included hospitals in Germany, Switzerland, and Spain. Furthermore, we leveraged the extant RNA-Seq data sets available from the Gene Expression Omnibus, which contained samples from the United States to validate our findings.

We recruited a total of 233 patients with mild to severe symptoms of COVID-19 for HLA sequencing analysis. In addition, we validated our findings in data from a public data set containing RNA sequencing data for a total of 99 patients with COVID-19 containing phenotypic information on requirement for intensive care, intubation or death nasopharyngeal swabs and/or detection of SARS-CoV-2 specific antibodies in the blood through enzyme-linked immunosorbent assay (ELISA). Sample collection took place during the first peak of the pandemic at five European Hospitals: Germany: Charite Universitätsmedizin Berlin (3 sites, total 92 patients, data set 1, DS1) 18, 19 ; Spain: Hospital Universitario de Valme, Sevilla (total 120 patients) and Switzerland: Kantonsspital Baden AG, Baden (total 21 patients, data set 2, DS2). All patients with COVID-19, who provided informed consent and were 18 years or older were included. Whole-blood samples, buffy coats, or peripheral blood mononuclear cells (PBMCs) were collected from all patients for DNA extraction during routine diagnostic venipuncture. In addition to clinical and laboratory data, we had access to first measured viral load data for the cohort from Germany (obtained by RT-PCR) 20 .

We used requirement for intensive care unit (ICU) admission, intubation, or death as well as a combined endpoint of all three outcomes as categories for HLA analysis.

We used the standard reference range for troponin T hs (<14ng/l) to define troponin elevation.

Acute cardiac injury was defined as elevation of troponin T hs (>14ng/l) without obvious signs for acute coronary syndrome. Furthermore, we directly used the troponin T hs levels to test for association. Troponin T hs levels were available for 66 patients.

Our protocol included blood samples obtained during routine clinically indicated venipunctures, which were then frozen at -80°C for subsequent deoxyribonucleic acid (DNA) extraction and sequencing. A minimal set of deidentified clinical data was collected to protect data privacy. At

Charite Universitätsmedizin Berlin procedures were performed within the framework of the Pa-COVID-19 protocol 18 .

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020. 12.21.20248121 doi: medRxiv preprint Given the exceptional situation of the pandemic and the international character of this study, there were differences amongst local ethics committees in consent procedures 7 . At each center, written informed consent was obtained from patients when possible, sometimes retrospectively if the patient was not able to give consent at the moment of sample collection. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

Aliquots of patient genomic DNA samples were diluted to the same concentrations in 96-well plates. To meet the challenges of a high-throughput project, further pipetting steps were performed with multichannel pipettes or on the epMotion 5075 pipetting robot (Eppendorf).

For each patient sample, eleven HLA genes were amplified using NGSgo®-AmpX v2

HLAGeneSuite kit (#7371662, GenDx). According to the design of this protocol, amplicons cover all class I HLA genes (HLA-A, -B, -C) and the most relevant parts of the class II HLA genes (HLA-DRB* 1, -DRB* 3/4/5, -DQB* 1, -DPA* 1, -DPB* 1, -DQA* 1), which have very long introns. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Publicly available data were downloaded from the Gene Expression Omnibus (GEO identifier GSE157103) and analyzed using the arcasHLA package, version 0.2.0 21 .

Ulitmately, correlation analysis was performed to compare HLA allele frequencies between all three data sets.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. cycles of PCR utilizing the KAPA UDI Primer Mix* (Roche Sequencing) and again purified using KAPA HyperPure Beads*. Amplified sample library concentration and size distribution was determined by Qubit dsDNA HS assay kit (ThermoFisher Scientific) with a Qubit™ 3 Fluorometer (ThermoFisher Scientific) and D5000 ScreenTape assay (Agilent Technologies) with a 4200

TapeStation system (Agilent Technologies). Eight amplified sample libraries were pooled prior to enrichment. For this purpose, 187,5 ng of each library was pooled into one well and the final volume was adjusted to 45 µl with nuclease-free water as designated by the manual KAPA HyperCap Workflow v3.0 (https://pim-eservices.roche.com/eLD/web/pi/en/home) and all further steps were performed following the recommendations of that manual.

These included hybridization of the amplified sample library pool to KAPA HyperExome Probes (Roche Sequencing) washing and recovery of the captured multiplex sample library, as well as amplification and purification of the enriched multiplex sample library. Final library pools were quantified by Qubit dsDNA HS assay kit with a Qubit™ 3 Fluorometer and correct size All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For a more detailed description of the analysis please see methods in the data supplement.

Composite disease score DS1 consisted of patients of the Charite cohort. For patients in DS1, we defined a composite score, including troponin T hs levels, death, ICU and intubation status (binned in five categories).

Then, we used multiple correspondence analysis (MCA; R package FactoMineR 23 , v. 2.3) to obtain a score derived from the selected variables, defined as the first dimension of the individual coordinates.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

Dominant model of association with the selected response variables was tested using Fisher's exact test (for categorical variables) or t-test (for continuous variables). The logarithm of Troponin T hs levels was used for the association test. In the analysis, we only considered alleles with a frequency in the given data set above 5% and with at least 5 individual carriers of the allele present. Other alleles were retained for the purpose of association testing, but not directly evaluated for association. The response variables differed between the three data sets analyzed. 

To obtain an empirical p-value of our selection / validation process, we have used a randomization test. We replicated the process 10,000 times, each time randomly assigning the real genotypes within a given data set to the patient identifiers. Then, for each allele, we calculated how many times the best p-values obtained in each of the three data set for associations with the different response variables within the randomization test are all lower than the p-values obtained with the non-randomized data set. The p-values obtained with randomization test were then recalculated using the Benjamini-Hochberg procedure to control for false discovery rate (FDR) 24 .

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

To test presence of subpopulations in DS1 and DS2, we leveraged exome derived variants. We used the R package SNPrelate, version 1.2.1, to process the VCF file and perform a principal components analysis. Next, we tested whether any of the principal components were associated with either intubation or ICU status or with the presence / absence of the identified risk allele.

Descriptive data on age, sex, intensive care management, maximum respiratory support during hospitalization and relevant comorbidities (hypertension, coronary artery disease, diabetes) of patients included in the primary and second data set are illustrated in table 1.

The median age was similar in the derivation cohort (DS1) and the two validation cohorts (DS 2 and 3), ranging from 57 to 61 years. The Spanish cohort consisted of more women (63%) than the German (33%) and the Swiss (24%) cohorts. In the Spanish cohort the prevalence of hypertension and diabetes was lower and patients were less likely to get intubated.

The genetic structures of DS1 and DS2 showed no indication of existing subpopulations based on principal component analysis of variants derived from whole exome sequencing data. None of the components was significantly associated with ICU or intubation status, even though few individuals were of different genetic background.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

Given the relatively small, but well-annotated DS1, we decided on a step-wise validation approach (Figure 1 ). In essence, we used DS1 as a discovery cohort to propose candidate alleles which then were validated using DS 2 (Switzerland/Spain) and DS 3 (United States).

Calculation of overall associations on a combined data set of all three cohorts (see Supplementary table 1) is prone to discovery of false positives, due to varying allele frequencies and percentages of apparently severe disease cases in the three data sets. To avoid this, as well as other potentially incorrect assumptions regarding variable distribution, we decided to test the obtained results using a randomization approach. In short, we repeated the whole selection / validation procedure 10,000 times, each time randomly assigning the obtained HLA genotypes to patients (separately in each cohort) and used the smallest p-values for associations in each data set as our test statistics. Such a randomization test allowed us to estimate how often the obtained combination of p-values from discovery and validation cohort occurs when there is no real association between alleles and response variables.

For selecting candidates, we defined a cutoff allele frequency of >5% and a minimum number of carriers (5) in the study population to ensure the relevance of the potential findings. Next, we tested the associations of the remaining alleles in DS1 after filtering with each of the proposed response variables considered to be proxies of disease severity: ICU and intubation status, troponin T hs levels, maximum WHO ordinal scale for clinical improvement score and a composite score. We selected alleles as candidate alleles, if they showed at least one association at p < 0.05 (not adjusted for multiple testing). We found 16 significant associations All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint of 11 alleles (Figure 2 ; Supplemental Table 2 ); the association between allele HLA C*03:03 and the composite score was significant after correcting for FDR.

Overall, the most frequent significant (p < 0.05) associations were with maximum WHO ordinal scale for clinical improvement score, intubation status, and troponin, while there were only two associations with ICU status and one with composite score.

Several of the test results indicated that the allele candidates were associated with greater disease severity. For example, while on average one third of the patients were intubated, 15 out of the 21 patients who carried the HLA-C* 04:01 allele were intubated. However, there were also alleles associated with milder disease course. The type II allele DQA1 *05:01 (present in 10 patients) was associated with lower troponin T hs levels; the common type I allele HLA-A* 01:01 (present in 25 patients) was weakly associated with lower WHO ordinal scale for clinical improvement score and lower fraction of intubated patients (24 vs 49%).

For DS 2 and DS 3, two response variables were generally available for all samples: ICU and intubation status. We therefore tested the association with ICU and intubation status for all candidate alleles. Furthermore, we tested association with troponin T hs levels in the Swiss cohort in DS2, for which this information was available. To determine whether a confirmation in one or both of DS2 and DS3 truly validates the allele candidates from DS1, we have used a randomization test, in which the selection/validation procedure was mimicked using resampled genotypes.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint In DS2, there was a significant (at FDR < 0.05) association between the allele HLA-DRB1* 11:04 and intubation status. Notably, amongst the 137 patients of DS 2, only 13 were treated in an ICU and 10 were intubated. Out of the 10 patients who were intubated, three were carrying the HLA-DRB1* 11:04 allele. This association was not confirmed by the randomization test. In DS3, the only significant associations were between the allele HLA-C* 04:01 and both ICU and intubation status (Figure 3; Supplemental Figure 1 ). The p-value obtained from the randomization test for this allele was < 0.004 after correcting for FDR (Supplemental Table 3 ), even though no association between HLA-C*04:01 could be detected in DS 2.

Finally, correlation analysis of allele frequencies overall revealed that HLA alleles had comparable frequencies between Germany, Switzerland, Spain, and the United States (Supplemental Figure 2) .

For DS1, first measured viral load data were available. Notably, measured viral load was not associated with severity of symptoms such as ICU/intubation status or troponine levels (Supplemental Figure 3 , Supplemental Table 1 ). There were five significant associations of initial viral load with HLA alleles at p<0.05, none of which were significant after correction for false discovery rate. The HLA-C* 04:01 allele was not significantly associated viral load. Given that viral load was not associated with disease severity in DS1 and that viral load data were not available for DS2 or DS3, we did not attempt to confirm whether the lack of association between HLA and viral load in DS1 was mirrored in the two other datasets.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

One possible explanation of the association between HLA alleles and COVID-19 severity is that these alleles occur at different frequencies in different risk groups. Therefore, we sought to evaluate if HLA-C* 04:01 occurs with higher frequency amongst older patients, who are at greater risk of developing severe symptoms of COVID-19. Indeed, patients who were intubated or admitted to the ICU were older overall (p-values from a two-sided t-test, were 0.003 and 0.014, respectively). However, HLA-C* 04:01 had an overall frequency of 0.12 and 0.14 in patients younger than 65 and a lower frequency, 0.067, in the high-risk group of patients older than 75 years.

To exclude other potential confounding effects, we tested the associations of all alleles in DS 1 with the covariates gender, age, weight, and body mass index (BMI). While there were seven alleles which showed a significant association at p < 0.05 (Supplemental Table 5 ), no association was significant after correction for multiple testing.

Furthermore, we tested if HLA-C* 04:01 is associated with higher CRP levels as a surrogate for systemic inflammation. However, there was only a trend that was not significant (Supplemental Figure 4 ). CRP correlated with the risk of intubation.

A possible explanation for the effect of an allele on disease severity might be abnormal binding affinity to SARS-CoV-2 peptides. To test that hypothesis, we used a previously described data set of putative (computed in silico) binding affinities. 15 Following an approach described by All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Iturrieta-Zuazo and colleagues 25 , we calculated the number of SARS-CoV-2 peptides, which bind either "tightly" (at < 50 mM) or "loosely" (at < 500 mM) for each allele. Using this approach, we discovered that HLA C*04:01 is among the ten alleles with the fewest predicted binding SARS-CoV-2 peptides (Figure 4) . Therefore, we sought to systematically test the hypothesis that the putative affinity to SARS-CoV-2 peptides is a correlate of disease severity. First, for each of the response variables (ICU and intubation status, troponin T hs levels, composite score) we tested whether the effect size is correlated with the number of potentially-binding peptides.

We included all alleles (not filtered for frequency) in this comparison. While in all data sets combined there were no large effects in alleles with many potential binding peptides, negative correlation was only significant in DS3 (Spearman test, p < 0.007, =0.27).

Next, for each patient, we calculated how many SARS-CoV-2 peptides can the type I alleles in that patient potentially bind, and tested whether there is an association between disease severity (using troponin T hs levels, intubation and ICU status and composite score as proxies) and that number. However, none of these tests showed a significant association.

Since polymorphisms in the KIR2DS4 gene in combination with the HLA*C 04:01 allele have been reported to increase viral load and lead to severe clinical course in patients with human immunodeficiency virus (HIV) 26 , we evaluated if presence of the KIR2DS4f variant was associated with our outcome variables (e.g. viral load, intubation). However, no association was identified. A combination of a KIR2DS4f variant with HLA*C 04:01 was identified in only four patients, of which only one was homozygous at the KIR2DS4 locus. This patient had a All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint severe clinical course, was intubated, and had highly elevated troponin T hs and maximum WHO ordinal scale for clinical improvement score.

In the beginning of the outbreak of the COVID-19 pandemic in Europe in spring 2020, an international collaboration of European centers was established to address the question, whether there were potential genetic host factors associated with severe clinical course in SARS-CoV-2. Samples were collected in Spain, Switzerland, and Germany 18 and subsequently processed in Germany for full-length sequencing of HLA genes in DNA samples.

We identified HLA-C* 04:01 as the most relevant risk allele, which was associated with a twofold risk of intubation when present in the form of at least one allele.

Importantly these findings were reproduced in an independent public data set obtained from patients with COVID-19 at Albany Medical Center, United States using RNA sequencing 17 . Using this approach, we demonstrated broad applicability of our findings and confirmed reproducibility and robustness of our results in data gathered through a distinct methodthe analysis of the transcriptome 27 . This is particularly relevant in the context of regional differences in allele frequencies 28, 29 . In that regard, HLA-B* 46:01 was shown to be associated with severe clinical course in SARS-CoV in Asia 14 . However, this allele is very rare in Germany, Spain, Switzerland and the United States 16 . In line with that, HLA-B* 46:01 was not represented in our European data set. In a correlation analysis we demonstrated that the frequencies of most alleles of the German cohort were similar to those in the cohorts from Switzerland, Spain, and the United States. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint After completing our stepwise analysis of data sets, final randomization and multiple comparisons of all three data sets confirmed that HLA-C* 04:01 was strongly associated with requirement of intubation. While this allele was not found to be significantly associated with disease severity in DS2, this data set included only a small number of patients with severe clinical course (13/133 patients treated at the ICU; 10/133 intubated, figure 3) . Therefore, detecting an existing association of HLA-C*04:01 was unlikely due to low statistical power, considering the observed effect size and allele frequency. Nonetheless, the combined effects observed in DS1 and DS3 were sufficient to reach a robust conclusion during randomization.

Another factor in which DS 2 differed from DS1, in particular the Spanish population, was that it consisted of a larger percentage of women (63% in Spain vs 33% in Germany). Importantly, DS2 was a representative sample of patients in Sevilla, where our recruiting center collected samples consecutively at the peak of the pandemic and by now has seen a similar proportion of women (60%) in all patients, who have been recruited since then (n=842). While our analysis did not reveal any association of specific HLA alleles with sex (supplemental table 5), it has been shown that female sex is associated with better outcomes 30 . This effect of sex may have masked the effect of HLA-C*04-01 validation in DS 2. Future research is necessary to investigate this hypothesis.

In addition to the strong and robust association of HLA-C* 04:01 and intubation with a hazard ratio of 2.1, there is also evidence in the literature suggesting a potential biological role of HLA-C* 04:01 in the defense of viral infections. In that regard, it has been shown that in patients infected with the human immunodeficiency virus (HIV), HLA-C* 04:01 in combination with polymorphisms in the KIR2DS4 gene was associated with high viral titers and severe clinical All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint course 26 . Moreover, HLA-C* 04:01 has been reported to occur at a higher frequency in COVID-19 patients than in the healthy population 31 .

The allele frequency of HLA-C* 04:01 is approximately 13% in Germany overall and 19% in German residents of Turkish origin 16 , suggesting that the presented findings may impact a relevant fraction of the German population. Similar numbers are found in Switzerland, where the allele frequency is about 16% and Spain, where an allele frequency of 15% has been reported 16 .

On the broader scale, it is notable that the highest allele frequencies of HLA-C* 04:01 worldwide have been observed in Oaxaca, Mexico (38%); Baloch, Iran (29%); Australian Aborigines (28%);

and African Americans (21%), while countries such as Japan and South Africa have very low frequency (4% each) 16 . While socioeconomic and classical risk factors, such as population age and comorbidities, are most likely the strongest predictors for severe clinical outcomes in patients with COVID-19, our data raise speculation that disease severity may be exacerbated in populations with high HLA-C* 04:01 frequency.

Since HLA-C* 04:01 is associated with viral load in HIV, we sought to evaluate if this was true for Sars-CoV-2. We did not find any association of HLA-C* 04:01 with first measured viral load of patients during their hospitalization. In addition, the first measured viral load in intubated patients did not differ from patients with mild disease. We support the common hypothesis that by the time the patients present with severe respiratory failure, the virus may have been already partially cleared from the body in some of them and the disease may be maintained through inflammatory or autoimmune mechanisms similar to other viral respiratory illnesses. 32 The dynamics of viral load in SARS-CoV 2 have been reported comprehensively in the All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint literature 20, 33, 34 . It may be beneficial to test for HLA-C* 04:01 in clinical trials to identify from which drug class this high-risk population benefits most.

It is also possible that viral load of patients with HLA-C* 04:01 may have been higher during the very first days of infection 35 , but since most patients only become symptomatic after approximately a week 36, 37 , this time window may have been missed in some patients of our cohort to see a potential relationship of HLA-C* 04:01 and viral loads measured during early infection. In general, there was no association of any specific HLA allele with first measured viral load in our cohort.

Exome sequencing revealed a combination of a KIR2DS4f variant with HLA*C 04:01 in only four patients. One of those patients was homozygous at the KIR2DS4 locus and had a severe clinical course. While these findings are interesting, the sample sizes of these subgroups are too small to draw any conclusions.

Notably, HLA affinity analysis revealed that HLA-C* 04:01 binding affinity to SARS-CoV-2 peptides was amongst the ten lowest HLA alleles. The effect size for the association between the allele and intubation status was strong. Delayed immune response due to low HLA binding affinity may be one potential biological explanation for the severe clinical course observed in patients with HLA-C* 04:01.

Alternatively, HLA-C* 04:01 may have led to worse outcomes by predisposing patients to a cytokine storm. To test that, we evaluated for a potential association of HLA-C* 04:01 with CRP serum levels as a surrogate for cytokine storm. Indeed there was a trend of higher CRP levels in HLA-C* 04:01, albeit this finding was not significant. CRP correlated with the risk of intubation, as shown in prior studies 38, 39 .

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint HLA-DQA1* 05:01, HLA-B* 08:01, and HLA DPB* 02:01 were associated with higher troponin T hs levels in DS1. However, this effect was not reproduced in the final validation in DS2 and DS3.

A major strength of this study was the execution of full-length sequencing of HLA alleles, as phasing of single nucleotide polymorphisms (SNPs) is frequently not feasible with the short reads typically used in full genome sequencing 40 . In that regard, any two alleles that differ only at regions that are further apart than the longest read length of the method used cannot be phased, resulting in ambiguity of HLA typing or miscalled alleles 40 . In addition, certain HLA regions, in particular structural variants and insertions, can only be covered with long reads as used in this study. We have confirmed findings from HLA full-length sequencing with HLA calls derived data from full exome sequencing data.

Our study is an important addition to prior HLA research in the field of COVID-19 that provided cumulative evidence for a potential predisposing susceptibility of HLA alleles for infection with COVID-19. It has been previously shown that specific HLA alleles were more common in patients infected with COVID-19 as compared to healthy individuals (e.g. HLA-DRB1* 15:01, HLA-DQB1* 06:02, HLA-DRB1*08, HLA-C*04:01) and it was extrapolated that these alleles may predispose to infection 31, [41] [42] [43] . It is not surprising that some of these alleles differed from ours, as we identified a genetic predictor specifically for severe clinical course amongst patients with COVID-19, while other groups compared healthy vs diseased. A recent genome wide association study (GWAS) identified blood group A as a major risk factor for COVID-19, but did not detect associations of the classical HLA loci with either COVID-19 infection or disease severity 7 . This study used target short read sequencing of HLA regions for a sub-cohort and investigated association with HLA C:04 only on a 2-digit rather than on the 4-digit level used in All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint this study. Both factors may contribute to a reduced power that made it impossible to detect the association that our approach finds supported in three data sets from different studies and in different populations.

In addition to host factors, it has been shown that genetic factors of the virus may affect affinity of host HLA to viral structures. In that regard, de Sousa and colleagues have shown that a single mutation in the wild type sequence of SARS-CoV-2 could affect peptide binding of the virus to HLA Class II alleles 44 .

In summary, we applied full-length HLA sequencing to patients with COVID-19 to enable identification of HLA alleles with high precision in a large international data set and validated our findings successfully in an entirely independent cohort. We used analysis of clinical and laboratory parameters, viral load data, and whole exome sequencing to evaluate for biological plausibility.

A limitation of this study was that in order to promptly respond to the COVID-19 pandemic with an international multi-center study, even patients with limited metadata were enrolled in this study. However, risk factors and clinical outcomes that we considered most relevant based on prior literature were collected and analyzed for all patients included in our cohorts.

Reproducibility of our data in an entirely independent cohort in Albany, United States supports the robustness of our data despite this limitation.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint severity. First, all alleles found in DS1 are filtered by frequency and tested for association with a number of variables considered to reflect the disease severity, such as ICU or intubation status.

Then, the allele candidates are tested for association with ICU and intubation status in DS2 and DS3. Finally, the whole procedure is repeated 10,000 times with genotypes randomly associated with the patient data (randomization test) and the obtained p-values are corrected for false discovery rate (FDR).

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Figure 3 Associations of HLA C*04:01 with categorical response variables. Each panel shows the difference between patients who were carrying the allele (HLA C*04:01 status: Present) and patients who did not carry the allele (HLA C*04:01 status: Absent). Colors correspond to variable status. Vertical axis shows the absolute number of patients. D1 -DS3: data sets 1 -3.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Figure 4 Correlation between the estimated effect size for the association between alleles and intubation status and the number of peptides putatively recognized by that allele. Each dot corresponds to one allele. Left column shows plots for DS1, right column shows plots for DS3; upper row shows plots for number of "tightly" binding peptides, lower row shows plots for number of "loosely" binding peptides. Dot size corresponds to the p-value in Fisher's exact test. Alleles showing significant associations with intubation status are labeled.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint SUPPLEMENTAL FIGURES Supplemental Figure 1 Associations of HLA C*04:01 with categorical response variables. Each panel shows the difference between patients who were carrying the allele (HLA C*04:01 status: Present) and patients who did not carry the allele (HLA C*04:01 status: Absent). Colors correspond to variable status. Vertical axis shows the frequencies of patients. D1 -DS3: data sets 1 -3.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Supplemental Figure 2 Supplemental Figure 3 Viral load at first measurement was not significantly associated with ICU / intubation status or troponin T hs levels.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Supplemental Figure 4 Evaluation for correlation of HLA* C 04:01 status with CRP serum levels. There was a trend of higher CRP levels in patients with HLA* C 04:01. However, these findings were not significant. CRP correlated with the risk of intubation.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint Supplemental preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 24, 2020. ; https://doi.org/10.1101/2020.12.21.20248121 doi: medRxiv preprint

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

First Case of 2019 Novel Coronavirus in the United States

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Aerosol emission and superemission during human speech increase with voice loudness

Clinical Characteristics of Coronavirus Disease 2019 in China

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Associations between blood type and COVID-19 infection, intubation, and death

Genetic mechanisms of critical illness in Covid-19

Transcriptomic biomarkers for the accurate diagnosis of myocarditis

Genomics and the multifactorial nature of human autoimmune disease

Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India

The genetic polymorphisms of HLA are strongly correlated with the disease severity after Hantaan virus infection in the Chinese Han population

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

Human leukocyte antigen susceptibility map for SARS-CoV-2

Allele Frequency Net Database

Large-Scale Multi-omic Analysis of COVID-19

Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)

Clinical and Virological Characteristics of

Hospitalized COVID-19 Patients in a German Tertiary Care Center during the First Wave of the SARS-CoV-2 Pandemic

Virological assessment of hospitalized patients with 23

FactoMineR: An R Package for Multivariate Analysis

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients

The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression

Transcriptome and genome sequencing uncovers functional variation in humans

How selection shapes variation of the human major histocompatibility complex: a review

A genomic perspective on HLA evolution

Male sex identified by global COVID-19 metaanalysis as a risk factor for death and ITU admission

Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and 34

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Evidence for transmission of COVID-19 prior to symptom onset

Associations of procalcitonin, C-reaction protein and neutrophilto-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China

Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients

Recipients Receiving Better HLA-Matched

Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study

HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy

HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients

Aligning sequence reads

SAMBLASTER: fast duplicate marking and structural variant read extraction

A quality control tool for high throughput sequence data

OptiType: precision HLA typing from next-generation sequencing data

Accurate and Efficient KIR Gene and Haplotype Inference from Genome Sequencing Reads with Novel K-mer Signatures

The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism

We thank all patients who participated in this study for giving us a chance to better understand this novel illness. We would like to express our condolences to the families and friends of patients who died from COVID-19.We thank the clinical teams at all our enrollment sites for supporting this project while fulfilling their clinical duties during this challenging time of the COVID-19 outbreak.We thank Gary R. Pasternack, MD, PhD for editorial assistance.We thank Anja Blüher und Sandra Sieman for excellent technical support. 

This study was partially funded by Roche Sequencing Solutions, Inc., which also provided material for exome sequencing. Bettina Heidecker, MD is an inventor on patents that use RNA for diagnosis of myocarditis. Juerg H. Beer, MD has received grant support from the Swiss National Science Foundation and of the Swiss Heart Foundation.